Sharemaestro Newsreel

Hims & Hers earnings analysis: questions answered and next catalysts

Haleon plc (HLN) files Form 6-K on cash tender offer for 2027 3.375% notes

Haleon plc has filed a Form 6-K announcing a cash tender offer for its outstanding 2027 3.375% Fixed Rate Notes, as detailed in an exhibit dated August 11, 2026. This filing serves to inform U.S. investors about the debt-related transaction. The offer targets debt …

Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7.1% - Here's Why

Aquestive Therapeutics (NASDAQ:AQST) saw its shares rise 7.1% to $4.595, with a market capitalization of approximately $574 million. The company's stock holds a consensus "Buy" rating from analysts with an average price target of $8.50, driven by its recent beat on quarterly earnings expectations. …

Is Hims & Hers Health (HIMS) Undervalued After Its Q2 2026 Loss?

Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down

Hims & Hers Health, Inc. HIMS reported quarterly adjusted loss per share of 10 cents in second-quarter 2026, against the year-ago period's adjusted earnings per share (EPS) of 17 cents. The metric was wider than the Zacks Consensus Estimate of loss per share of …

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over …

Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"

Indivior Pharmaceuticals Inc. (INDV) is identified as a strong growth stock due to its favorable Zacks Growth Style Score and top Zacks Rank. The article highlights three key factors: strong projected earnings growth of 46.4%, robust year-over-year cash flow growth of 36%, and promising …

BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance

BioCryst Pharmaceuticals (BCRX) is potentially 54% undervalued, with a fair value estimated at $21.30 per share against a last close of $9.84. This outlook follows a strong Q2 2026 report showing higher revenue, improved net income, and a raised full-year revenue forecast, coupled with …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% - What's Next?

BioCryst Pharmaceuticals (NASDAQ:BCRX) saw its stock price increase by 6% in mid-day trading following strong quarterly results, where the company exceeded EPS and revenue expectations. Analysts maintain a "Moderate Buy" consensus with an average price target of $20.60, despite varied individual ratings. Institutional investors …

Will Hims & Hers’ Higher 2026 Revenue Guidance Amid Rising Losses Change HIMS’s Investment Narrative?

Hims & Hers Health, Inc. reported second-quarter 2026 sales of US$753.21 million, up from US$544.83 million a year earlier, but moved from net income of US$42.51 million to a net loss of US$86.29 million, while also raising full-year 2026 revenue guidance to between US$3.10 …

Eton Pharmaceuticals (NASDAQ:ETON) Shares Down 4.5% - Here's Why

Eton Pharmaceuticals (NASDAQ:ETON) saw its shares drop 4.5% on Tuesday, trading at $41.70 with significantly lower volume. Despite missing quarterly EPS estimates, the company exceeded revenue expectations, and analysts generally maintain a "Moderate Buy" rating with an average price target of $54.50. Recent insider …

AMPH (AMPH) schedules Rule 144 stock sale tied to RSU vesting

Amphastar Pharmaceuticals (AMPH) has filed a Rule 144 notice for the proposed sale of 7,973 shares of common stock, valued at $161,931.63, through UBS Financial Services Inc. The sale is scheduled for August 11, 2026, and is linked to multiple Restricted Stock Unit (RSU) …

Midday Need to Know: Gold surges, home sales decrease & more

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Wall Street's major market averages are relatively muted on Tuesday as traders focus on developments related to the Middle East and the reopening of the Strait of Hormuz. The blue-chip Dow (DJI [https://seekingalpha.com/symbol/DJI]) …

Hims & Hers stock trims losses following quarterly results

What happened: Hims & Hers Health (HIMS) stock declined 3% before trimming losses on Tuesday. What's behind the move: Shares were volatile after the telehealth company swung to a loss of $0.37 per share in the second quarter from a profit of $0.17 a …

Aurora Cannabis jumps after Curaleaf says it will make a takeover offer (update) (ACB:NASDAQ)

Aurora Cannabis (ACB) stock surged 21% following an announcement from Curaleaf Holdings (CURLF) about its plan to make a $4 per share takeover bid. The offer, which includes both cash and Curaleaf shares, represents a premium over Aurora's recent trading prices. Aurora Cannabis has …

OrganiGram Holdings Inc. (OGI) News, Articles, Events & Latest Updates

This article provides recent news and updates on OrganiGram Holdings Inc. (OGI), including its Q3 2026 earnings report where it beat revenue estimates despite a loss. It also covers other health care stocks moving in the pre-market session and announcements regarding Organigram's business updates …

Hims & Hers Q2 revenue beat offset by wider-than-expected loss

Hims & Hers Q2 revenue beat offset by wider-than-expected loss Proactive uses images sourced from Shutterstock Hims & Hers Health (NYSE:HIMS) delivered mixed second-quarter results, with revenue beating Wall Street expectations while its quarterly loss came in wider than analysts had forecast as the …

FTC Continues Investigation into Hims & Hers Health, Inc.

Lowey Dannenberg, P.C. has filed a class action complaint against Hims & Hers Health, Inc., alleging the company misrepresented privacy and shared sensitive health information without consent. This complaint follows a civil enforcement action by the FTC and other state bodies against Hims & …

Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO

For Immediate Release Chicago, IL – August 11, 2026 – Stocks in this week's article are OptimumBank Holdings Inc. OPHC, EuroDry Ltd. EDRY, Enova International Inc. ENVA, Anika Therapeutics Inc. ANIK and The GEO Group Inc. GEO. 5 Stocks with Recent Price Strength to …

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Kodiak Sciences KOD announced that it initiated a global late-stage ALTO study evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational bispecific therapy that targets IL-6 and VEGF for the treatment of retinal vascular diseases. Patient enrollment is ongoing. DME …

Harrow Q2 Earnings Call Highlights

Key Points Interested in Harrow, Inc.? Here are five stocks we like better. Q2 revenue rose 11% year over year to $70.7 million, driven by stronger demand for VEVYE, IHEEZO and specialty products. Harrow reiterated its full-year revenue guidance of $350 million–$365 million and …

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors in BioCryst Pharmaceuticals, Inc. BCRX need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2026 $2 Put had some of the highest implied volatility of all equity options today. What …

Elanco's CLiK(TM) Extra (Dicyclanil Topical Suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also …

Liquidia earnings in focus as YUTREPIA launch faces patent test

Liquidia Technologies Inc. is reporting its second-quarter results with investors focusing on the commercial success of its new pulmonary hypertension drug, YUTREPIA, and the ongoing patent litigation. Analysts anticipate strong earnings and revenue growth, though the stock's recent surge reflects both high expectations and …

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply alter valuations by changing expectations for a drug's safety, efficacy …

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Moody's Ratings has upgraded Teva Pharmaceutical Industries Ltd.'s corporate credit rating to Baa3 from Ba1, achieving investment-grade status with a stable outlook. This upgrade reflects Teva's successful "Pivot to Growth" strategy, including innovative products, an expanded pipeline, and continued debt reduction. The recognition from …

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst Pharmaceuticals achieved profitability in 2025 and saw a significant revenue increase in Q2 2026, leading to speculation about its acquisition. Takeda is considered the top potential buyer due to BioCryst's drug navenibart directly threatening Takeda's HAE franchise, with AstraZeneca ranking second. Other potential …

Haleon unit launches tender offer for $2 billion 2027 notes

Haleon US Capital LLC, a wholly owned subsidiary of Haleon plc, has launched a tender offer to purchase all outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. This tender offer is part of Haleon's strategy to manage and optimize its debt portfolio, …

Haleon offers to buy back $2B of 3.375% notes due 2027 to optimize debt portfolio.

Haleon plc's subsidiary, Haleon US Capital LLC, has launched a tender offer to repurchase up to $1.999 billion of its 3.375% senior notes due in March 2027. This strategic move aims to optimize the company's debt portfolio and enhance financial flexibility, contingent on the …

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 25.9% year on year to $266 million. On the other hand, the company's …

InterCure Ltd. (INCR) shareholders back proposal at August 11, 2026 special meeting

Why Is Hims & Hers Health Stock Falling Tuesday?

Wall St set for higher open as investors weigh fresh US-Iran peace deal reports

By Avinash P and Purvi Agarwal Aug 11 (Reuters) - Wall Street's main indexes were poised to open higher on Tuesday as investors welcomed a report suggesting the United States and Iran were close to "some sort ‌of an arrangement" to end six months …

Organigram Global Inc. Q3 Results: Net revenue rises 49% YoY

Organigram Global Inc. reported record Q3 FY26 results, with net revenue increasing by 49% year-over-year to $105.8 million and adjusted EBITDA jumping by 136% to $13.4 million. This significant growth was primarily driven by the acquisition of Sanity Group, which contributed €25 million in …

Earnings call transcript: OrganiGram posts record Q3 2026 revenue as stock rises

OrganiGram Global reported record fiscal Q3 2026 net revenue of CAD 105.8 million and adjusted EBITDA of CAD 13.4 million, driven largely by the consolidation of Sanity Group. The acquisition helped increase international revenue to 35% of total revenue. Despite the strong performance and …